VEGF and Cyclin D1 positively contribute to tumor growth by VHL-deficient RCC cells.

<p>A. Lysates from 786-O cells stably expressing VHL, the SCR or the VEGF shRNAs were prepared and assayed with VEGF ELISA. B. 786-O <i>VHL-/</i>- cells infected to produce SCR or VEGF-1137 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors were excised and weighed. Eight tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001 according to a Mann-Whitney U statistic analysis. C. Representative photographs of tumors analyzed in Figure 3B. Left: Tumor from cells expressing SCR; Right: Tumor from cells expressing VEGF-1137. D. Total cell lysates of 786-O cells stably expressing VHL, the SCR or the Cyclin D1 shRNAs were immunoblotted with the indicated antibodies. E. 786-O <i>VHL-/</i>- cells infected to produce SCR or CCND1-2322 were injected subcutaneously into the flanks of nude mice. Approximately 8-10 weeks later, tumors were excised and weighed. Eight tumors per line were analyzed. Error bars = standard error of the mean. P<=0.001 according to a t-test. F. Representative photographs of tumors analyzed in Figure 3E. Left: Tumor from cells expressing SCR; Right: Tumor from cells expressing CCND1-2322.